Published By : 13 Oct 2016 | Published By : QYRESEARCH
Any drug is composed of two components. The first one is Active pharmaceutical ingredients (API) which are the most important ingredient while the other one is known as excipient. Excipients are the inactive substances in a drug whereas API is the chemically active substance which is meant to perform the desired effect on the body. API are also referred as ‘bulk pharmaceuticals’ and are considered as the base of the industry. North America contributes to more than 45% of the global market for API contract manufacturing but production is not very cost efficient in western countries. Emerging economies of Asia Pacific, India and China in particular, are fast growing as the hub of API contract manufacturing.
According to Boehringer Ingelheim GmbH, these two countries already account for manufacturing of 40% of the APIs used in the U.S and percentage is expected to double up in next ten years. Here are a few reasons why India and China are such lucrative API manufacturing destination for several pharmaceutical companies.
Conclusion: With trade and transport sector in healthy conditions, there is no reason why API contract manufacturing companies should not look at India and China for their production purposes.